The FDA has approved an expanded label for GlaxoSmithKline’s new Trelegy Ellipta inhaler, allowing it to be used in a broader population of patients with chronic obstructive pulmonary disease ...

Having begun working together in December 2015, the partners are now ready to bring to market their custom digital sensor for GSK’s asthma and COPD inhaler, Ellipta. The sensor attaches to the ...

AstraZeneca’s Symbicort inhaler accounts for most of its inhalation ... Meanwhile GSK's lead inhalers include Trelegy Ellipta, projected to bring $3.3bn in 2024 sales, followed by Relvar/Breo ...